06.11.2020 • News

Lummus Wins Russian Ethylene Contract

Lummus Technology has won a contract to supply 14 cracking furnaces for a gas chemical complex near Ust-Luga, Leningrad Oblast in Russia.

The contract was awarded within the framework of an engineering procurement and construction contract between China National Chemical Engineering & Construction Corporation Seven (CC7) and the Baltic Chemical Plant.

Lummus will provide engineering and its proprietary Short Residence Time (SRT) VI cracking furnaces, which will give a total ethylene capacity (crackers 1 and 2) of up to 3 million t/y. 

  
“The benefits offered by Lummus Technology include significant reduction in the output of by-products and specific consumption of utilities,” said Konstantin Makhov, general director of Baltic Chemical Plant. “The process also offers feedstock flexibility as it is possible to feed up to 10% propane in case of ethane shortage.”

CC7’s vice president Long Haiyang, also commented: “This is the first experience of partnering between Lummus Technology and CC7 for [an] ethylene integration project both in Russian and international markets. The relationships between the two companies have been evolving, and cooperation experience gained in this project will build a reliable foundation for future strategic partnership in the international market.”
  
The Baltic Chemical Plant complex is expected to produce about 3 million t/y of PE. A start-up date has not been disclosed.

Author: Elaine Burridge, Freelance Journalist

Lummus Technology will supply 14 cracking furnaces for a chemical complex near...
Lummus Technology will supply 14 cracking furnaces for a chemical complex near Ust-Luga in Russia. Lummus will provide engineering and its proprietary Short Residence Time cracking furnaces, which will give a total ethylene capacity (crackers 1 and 2) of up to 3 million t/y. (c) PilMo Kang

Company

Logo:

Lummus Technology

5825 North Sam Houston Pkwy W #600
77086 Houston, TX
US

Company contact







Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

most read